EEG-based Depth of Anesthesia-monitoring, Effects on Dosage and Cognition
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04529304 |
|
Recruitment Status :
Recruiting
First Posted : August 27, 2020
Last Update Posted : March 26, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Postoperative Complications Delayed Emergence From Anesthesia Cognitive Dysfunction | Device: Bilateral Bispectral Index and EEG | Not Applicable |
It has been over 80 years since Gibbs et al showed how the electroencephalogram (EEG) systematically changed in concurrence with increasing doses of hypnotic drugs such as penthobarbital and Ether. The study concluded that "Electroencephalography may therefore be of value in controlling depth of anesthesia and sedation". In spite of a solid documentation of the systematic connection between dosing of anesthetic drugs, EEG-patterns and level of sedation/anesthesia , EEG-based DoA has not become a part of standard of care in anesthetic management. There is abundant evidence of how different anesthetic drugs leads to characteristic fluctuations in human brain electrical activity, relating to depth of anesthesia, anesthetic drug of choice, and age . These anesthetic induced fluctuations are readily visible as changes in the patients EEG.
Anesthetic drugs are usually administered in pharmacological models based on a population taking into account their age, weight and height. However, there is a significant difference in how patients respond to these models. In adults there is evidence that the doses needed to achieve consciousness varies with a factor of 2 above and below suggested doses. In under-dosing of anesthetics there is a risk of peroperative awareness . On the other hand there is also evidence that overdosing of anesthetics has harmful effects; children receiving more than 4% Sevoflurane can demonstrate epileptiform activity , and adults overdosing into "burst suppression" during anesthesia has a higher risk of postoperative delirium (POD) and increased occurrence of postoperative cognitive dysfunction (POCD) .
Bispectral Index (BIS) is an algorithm developed by Aspect Medical Systems in 1994, which is based on weighted sums of EEG subparameters to present an index from 0 to 100 for depth of anesthesia, where 100 is wide awake, and 0 is an isoelectric EEG. The BIS target for a deep enough anesthesia is set to be between 40 and 60. The BIS number is often in concurrence with other clinical observations related to anesthetic depth, however there is also an experience of divergence. BIS and other EEG-based indices are programmed from adult cohorts, and cannot be directly trusted in children, or the elderly . There is also an incapability in these preprogrammed indices (BIS and other) to integrate how specific anesthetic drugs affect the EEG, and thenceforth the BIS value. An example of this is how the drug Ketamine induces a specific gamma-frequency in the EEG, which the BIS-index translate as a lighter anesthesia, even though the drug is administered "on top of" an already deep level of anesthesia.
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 100 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Intervention Model Description: | Two groups with 50 participants in each group. We want to compare one group with visible EEG-monitor with a group where the EEG monitor is invisible to the anesthetic team. |
| Masking: | Triple (Participant, Care Provider, Outcomes Assessor) |
| Masking Description: | Patient is blinded to intervention. Outcome assessoring done by patient/IPAD-solution from CANTAB, patient status assessed by blinded care-provider (nurse) |
| Primary Purpose: | Other |
| Official Title: | EEG-based Depth of Anesthesia-monitoring During General Anesthesia - Effects on Time to Wake-up and Post-operative Cognition |
| Actual Study Start Date : | January 8, 2021 |
| Estimated Primary Completion Date : | March 15, 2022 |
| Estimated Study Completion Date : | December 20, 2022 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Visual EEG
Individual dosing of anesthetic medications based on EEG AND other standardized clinical observations (BP, HR)
|
Device: Bilateral Bispectral Index and EEG
raw-EEG and spectrographic EEG-visualization based on the Medtronic Device "Bilateral BiSpectral Index" |
|
Experimental: Blinded EEG
Individual dosing of anesthetic medications based on standardized clinical observations (BP, HR).
|
Device: Bilateral Bispectral Index and EEG
raw-EEG and spectrographic EEG-visualization based on the Medtronic Device "Bilateral BiSpectral Index" |
- EEG-based Depth of anesthesia-monitoring and dosage of anesthetic medications [ Time Frame: 24 hours ]Summarizing the total amount of anesthetic drugs used, mg/kg/hr
- EEG-based Depth of anesthesia-monitoring and dosage of vasopressor medications during anesthesia [ Time Frame: 24 hours ]Summarizing the total amount of vasopressor drugs used, micg/kg/min
- EEG-based Depth of anesthesia-monitoring and time to wake-up after surgery [ Time Frame: 24 hours ]Time from the end of intravenous infusion of anesthetic - to motoric and verbal response.
- Evaluation of cognitive function using CANTAB-MCI [ Time Frame: 1 day preoperatively to 24 hours after wake-up ]Baseline assessment 1 day preoperatively, assessment 2-3 hours after wake-up, and 24 hours after wake-up using CANTAB-MCI
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 85 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria
.
Participants are eligible to be included in the study only if all of the following criteria apply:
Age
-
Participant must be above the age of 18 years , at the time of signing the informed consent.
Sex
-
Male and/or female
Informed Consent
-
Capable of giving signed informed consent as described in protocol which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in the protocol
Exclusion Criteria
Participants are excluded from the study if any of the following criteria apply:
- Psychiatric disorders
- Pregnancy
- Breast feeding
- Using antiepileptic drugs.
- Central neurological disease
- Unable to complete baseline CANTAB-test.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04529304
| Contact: Anders Aasheim, Master | +4748129280 | uxanim@ous-hf.no | |
| Contact: Luis G Romundstad, MD, PhD | luirom@ous-hf.no |
| Norway | |
| Oslo University Hospital | Recruiting |
| Oslo, Norway, 0124 | |
| Principal Investigator: | Luis G Romundstad, MD, PhD | Oslo University Hospital |
Documents provided by Luis George Romundstad, Oslo University Hospital:
| Responsible Party: | Luis George Romundstad, Principal Investigator, Medical Doctor, Oslo University Hospital |
| ClinicalTrials.gov Identifier: | NCT04529304 |
| Other Study ID Numbers: |
2019/32173 |
| First Posted: | August 27, 2020 Key Record Dates |
| Last Update Posted: | March 26, 2021 |
| Last Verified: | March 2021 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | Yes |
| Plan Description: | Data storage and management will follow GCP and GDPR requirements. Data sharing after end of study will follow the current data sharing policy at Oslo University Hospital. Data set can be made available for journal peer review process. |
| Supporting Materials: |
Study Protocol Statistical Analysis Plan (SAP) Informed Consent Form (ICF) Clinical Study Report (CSR) Analytic Code |
| Time Frame: | After end of study, 2025, and 5 years. |
| Access Criteria: | Access through application to study contactpersons. |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Depth of Anesthesia Monitoring Post operative cognitive dysfunction (POCD) |
|
Postoperative Complications Delayed Emergence from Anesthesia Cognitive Dysfunction Pathologic Processes |
Cognition Disorders Neurocognitive Disorders Mental Disorders |

